CClinicalTrials.gg
RecruitingNCT05906082Updated Aug 7, 2025

Vape-Free Text-Messaging: Pilot Study

An interventional study of E-cigarette cessation text-messaging intervention and Standard care control using standard national resources in E-cigarette Use, sponsored by Jovan Gwon, PhD, RN, FIAAN. Recruiting at 1 site in United States. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Jovan Gwon, PhD, RN, FIAAN · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Study summary

This is a small pilot randomized controlled trial to evaluate the feasibility, acceptability, and preliminary efficacy of the e-cigarette cessation text-messaging intervention with young adults in rural areas.

02

Conditions studied

  • E-cigarette Use

Browse trials for

03

In context

Vaping

160 studies on the registry are indexed under Vaping; 72 are open to participants now.

This study's planned enrollment of 50 is below the median of 110 across 135 interventional studies indexed under Vaping.

Browse Vaping studies →

Lead sponsor

This is the only study on the registry with Jovan Gwon, PhD, RN, FIAAN as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • English speaking
  • 18-24 years
  • everyday e-cigarette use in the past month
  • ownership of a mobile phone or smartphone with texting and internet access abilities
  • knowledge of how to use text messages
  • plan on quitting e-cigarette use within one month
  • home address in a rural county of Wisconsin, Minnesota, North Dakota, and South Dakota

Exclusion criteria

Exclusion Criteria:

  • Individuals who reported use of other tobacco products (e.g., cigarettes, smokeless tobacco) than e-cigarettes in the past month
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intervention (E-cigarette cessation text-messaging intervention)

    Behavioral: E-cigarette cessation text-messaging intervention

  • Active comparator
    Standard care (Standard care control using standard national resources)

    This standard care group will receive standard care resources from smokefree.gov.

    Behavioral: Standard care control using standard national resources

Interventions

  • BehavioralE-cigarette cessation text-messaging intervention

    This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.

  • BehavioralStandard care control using standard national resources

    This is the standard care with national resources from smokefree.gov.

06

What researchers measure

Primary outcomes

  1. Number of participants recruited and randomized

    Number of participants recruited and randomized

    Time frame: Throughout 12 months

  2. Self-reported proportion of text messages read

    Proportion of text messages read during the intervention or standard care at 1 month

    Time frame: At 1 month

  3. Retention rates (proportion of participants remained until 1 month post-intervention from enrollment)

    Proportion of participants from enrollment to 1 month post-intervention or standard-care

    Time frame: At 1 month

  4. Level of acceptability of the intervention

    1. When you had received our text messages from our VapeFreeTXT program 1 month ago, how many of our text messages did you read on a typical day? Not at all (1) Read about 25% messages (2) Read about half messages (3) Read about 75% messages (4) Read the entire messages (5) 2. How useful was our VapeFreeTXT program in helping you quit vaping? Not at all useful (1) Slightly useful (2) Moderately useful (3) Very useful (4) Extremely useful (5) 3. Did our VapeFreeTXT program make you think about quitting vaping? Not at all (1) Probably not (2) Neither yes nor no (3) Probably yes (4) Definitely yes (5) 4. Do you think our VapeFreeTXT program will change your vaping? Not at all (1) Probably not (2) Neither yes nor no (3) Probably yes (4) Definitely yes (5) 5. Would you recommend this program to a friend or others? Not at all (1) Probably not (2) Neither yes nor no (3) Probably yes (4) Definitely yes (5)

    Time frame: At 1 month

  5. Proportion of salivary cotinine samples returned

    Proportion of salivary cotinine samples returned to the office lab for cotinine analysis

    Time frame: At 1 month

  6. Self-reported 7-days point prevalence abstinence from ENDS and other tobacco

    Self-reported 7-days point prevalence abstinence from ENDS and other tobacco

    Time frame: At 1 month

  7. Concentration of cotinine in saliva

    Biochemically verified abstinence evaluated by salivary cotinine samples

    Time frame: At 1 month

  8. Nicotine dependence (Penn State Electronic Cigarette Dependence Index)

    Nicotine dependence (minimum 0 to maximum 20, higher scores mean a worse outcome.)

    Time frame: At 1 month

07

Study locations

1 of 1 sites recruiting
  • University of Wisconsin-Milwaukee
    Milwaukee, Wisconsin 53211, United States
    • Seok Hyun Gwon, PhD, RN · Contact · gwon@uwm.edu · 4142296462
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05906082
Lead sponsor
Jovan Gwon, PhD, RN, FIAAN
Responsible party
Jovan Gwon, PhD, RN, FIAAN (Associate Professor, University of Wisconsin, Milwaukee) — Sponsor-investigator
First posted
Jun 15, 2023
Start date
May 25, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion